Skip to Content
Merck

Skip To

C0737

Cilostazol

≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder

Synonym(s):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
10 mg
Check Cart for Availability
CLP 178,000
50 mg
Check Cart for Availability
CLP 703,000

About This Item

Empirical Formula (Hill Notation):
C20H27N5O2
CAS Number:
Molecular Weight:
369.46
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:

CLP 178,000


Check Cart for Availability

Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Cilostazol, ≥98% (HPLC), powder

Quality Level

assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: 10 mg/mL, clear

originator

Otsuka Pharma

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

General description

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Application

Cilostazol has been used:
  • to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
  • in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
  • to induce adenosine triphosphate (ATP) release in white adipocytes

Biochem/physiol Actions

Phosphodiesterase III (PDE3) inhibitor

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
1134153PHR1503SML1447
form

powder

form

-

form

-

form

powder

assay

≥98% (HPLC)

assay

-

assay

-

assay

≥98% (HPLC)

Quality Level

100

Quality Level

-

Quality Level

300

Quality Level

100

solubility

DMSO: 10 mg/mL, clear

solubility

-

solubility

-

solubility

H2O: 2 mg/mL, clear (warmed)

color

off-white

color

-

color

-

color

white to beige

originator

Otsuka Pharma

originator

-

originator

-

originator

-


Still not finding the right product?

Explore all of our products under Cilostazol


pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Articles

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.


Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)



Global Trade Item Number

SKUGTIN
C0737-10MG04061833451540
C0737-50MG04061832897585

Questions

Reviews

No rating value

Active Filters